Thurston, Springer, Miller, Herd & Titak, Inc. Crispr Therapeutics Ag Transaction History
Thurston, Springer, Miller, Herd & Titak, Inc.
- $330 Million
- Q3 2024
A detailed history of Thurston, Springer, Miller, Herd & Titak, Inc. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Thurston, Springer, Miller, Herd & Titak, Inc. holds 1,326 shares of CRSP stock, worth $67,413. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,326
Previous 1,346
1.49%
Holding current value
$67,413
Previous $72,000
13.89%
% of portfolio
0.02%
Previous 0.03%
Shares
2 transactions
Others Institutions Holding CRSP
# of Institutions
493Shares Held
58MCall Options Held
1.1MPut Options Held
1.9M-
Capital International Investors Los Angeles, CA7.93MShares$403 Million0.07% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl7.5MShares$381 Million3.35% of portfolio
-
State Street Corp Boston, MA2.99MShares$152 Million0.01% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.2.97MShares$151 Million0.1% of portfolio
-
Nikko Asset Management Americas, Inc.2.97MShares$151 Million1.61% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $3.97B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....